Article Information
History
- December 8, 2021.
Article Versions
- Version 1 (December 8, 2021 - 06:50).
- You are currently viewing Version 2 of this article (December 8, 2021 - 15:27).
- Version 3 (December 11, 2021 - 15:19).
- View Version 4, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Author Information
- Alexander Wilhelm1,
- Marek Widera1,6 (marek.widera{at}kgu.de),
- Katharina Grikscheit1,
- Tuna Toptan1,
- Barbara Schenk1,
- Christiane Pallas1,
- Melinda Metzler1,
- Niko Kohmer2,
- Sebastian Hoehl1,
- Fabian A. Helfritz3,
- Timo Wolf4,
- Udo Goetsch5 and
- Sandra Ciesek1
- 1 Institute for Medical Virology, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany;
- 2 Institute for Medical Virology, University Hospital, Goethe University Frankfurt am Main, Germany;
- 3 Buergerhospital Frankfurt, Nibelungenallee 37-41, 60318 Frankfurt am Main, Germany;
- 4 Department of Internal Medicine, Infectious Diseases, University Hospital Frankfurt, Goethe University Frankfurt, 60596 Frankfurt am Main, Germany;
- 5 Health Protection Authority of the City of Frankfurt am Main, 60313 Frankfurt am Main, Germany
- ↵* Corresponding author; email: marek.widera{at}kgu.de
Posted December 08, 2021.
Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies
